were climbing after the company said third-quarter earnings beat the analyst consensus due to strong revenue growth.
The company also confirmed its full-year 2003 guidance and said fiscal year 2004 earnings will fall in line with analysts' consensus estimates.
Shares were up 8%, or $1.73, to $23.07 in midday trading.
"Sales and gross profits have grown as a result of general price increases, new customer contracts and renewals of group pricing contracts at substantially higher prices," said Edward L. Gallup, chief executive of Immucor.
The company earned $3.7 million, or 28 cents a share, in the quarter ended Feb. 28, compared with $2.5 million, or 21 cents a share, a year ago. Analysts were expecting the company to earn 25 cents a share, on average.
Revenue was $25.1 million, up from last year's $21.1 million.
Looking to full-year 2003 results, the company expects to earn $13.7 million to $14.4 million, or $1.03 to $1.08 a share, on revenue of $95.5 million to $97 million. Analysts expect $1.04 a share on revenue of $97 million.
For 2004, Immucor expects net income of $17.1 million to $19.1 million, or $1.20 to $1.34 a share, on revenue of $106 million to $109 million. Analysts expect revenue slightly higher at $110.9 million, on average, and EPS of $1.24.
Norcross, Ga.-based Immucor provides automated instrument-reagent systems to the blood transfusion industry.